5Y Capital

5Y Capital is a Shanghai-based venture firm with a high-conviction approach to backing visionary entrepreneurs in life sciences and deep tech, including computational biology platforms. The firm is known for concentrated portfolio positions and a willingness to underwrite serious technical and scientific risk, which gives it a different profile from the broader Chinese venture mainstream.

The healthcare thesis covers biotech, life sciences tools, and AI and machine learning applied to healthcare. 5Y Capital invests where the underlying science is defensible, the founding team is exceptional, and the commercial trajectory has the potential for category leadership. The high-conviction model means the firm will pass on many opportunities to concentrate around fewer, larger positions where it sees genuine differentiation.

The firm writes $5M to $25M checks across Seed, Series A, Series B, and Growth, which is the multi-stage coverage that supports concentrated positions over multiple rounds. Geographic focus is China, with portfolio companies routinely expanding into international markets, and the firm’s stage breadth means it can accompany breakout companies through their full venture lifecycle. Founders should expect rigorous diligence on scientific and commercial fundamentals.

The team operates with a pronounced founder-centric philosophy and indexes heavily on the quality of founding teams and the durability of technical insight. Specific partner names are not provided in the source data, and founders should engage through 5Y Capital’s English-language website and expect serious technical diligence from partners with relevant scientific backgrounds.

The approach is visionary-founder-centric and high-conviction. 5Y Capital invests when it sees both exceptional teams and durable technical edges, and is willing to take concentration risk to support breakout companies. The firm is a strong fit for ambitious life sciences and deep tech founders in China who want a high-conviction lead investor capable of accompanying them across multiple rounds. Founders building incremental businesses or those operating without a visionary technical thesis may find less alignment.